Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Roivant Sciences Ltd WT (ROIVW)

Roivant Sciences Ltd WT (ROIVW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 124,800 K
  • Annual Income, $ 4,349 M
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/11/25
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.30
  • Number of Estimates 3
  • High Estimate -0.22
  • Low Estimate -0.39
  • Prior Year -0.26
  • Growth Rate Est. (year over year) -15.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.57 +7.00%
on 08/17/23
3.21 -14.33%
on 08/02/23
-0.49 (-15.12%)
since 08/01/23
3-Month
1.92 +43.23%
on 06/27/23
4.00 -31.25%
on 07/06/23
+0.65 (+30.95%)
since 06/01/23
52-Week
0.22 +1,160.89%
on 09/30/22
4.00 -31.25%
on 07/06/23
+2.27 (+472.32%)
since 09/01/22

Most Recent Stories

More News
Kinevant Sciences Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis

ROIVW : 2.75 (-3.85%)
ROIV : 11.57 (+0.61%)
Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis

ROIVW : 2.75 (-3.85%)
ROIV : 11.57 (+0.61%)
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update

ROIVW : 2.75 (-3.85%)
ROIV : 11.57 (+0.61%)
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024

ROIVW : 2.75 (-3.85%)
ROIV : 11.57 (+0.61%)
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

ROIVW : 2.75 (-3.85%)
ROIV : 11.57 (+0.61%)
Roivant Sciences to Report Financial Results for the Quarter Ended June 30, 2022 on Monday, August 15, 2022

Investor call and webcast scheduled for Monday, August 15 at 8:00 a.m. EDTRoivant will host an investor day on Wednesday, September 28 at 11:00 a.m. EDT ...

ROIVW : 2.75 (-3.85%)
ROIV : 11.57 (+0.61%)
Roivant Sciences Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 and Provides Business Update

Potential blockbuster VTAMA® (tapinarof) approved by FDA for the treatment of plaque psoriasis at end of May 2022 is the first topical novel chemical...

ROIVW : 2.75 (-3.85%)
ROIV : 11.57 (+0.61%)
Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus

Brepocitinib is a potential first-in-class dual, selective inhibitor of TYK2 and JAK1; in all five placebo-controlled studies completed to date, oral...

ROIVW : 2.75 (-3.85%)
ROIV : 11.57 (+0.61%)
PFE : 26.36 (+2.29%)
Roivant Sciences to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 on Tuesday, June 28, 2022

Investor call and webcast scheduled for Tuesday, June 28 at 8:00 a.m. EDT BASEL, Switzerland and LONDON and NEW YORK and BOSTON, June 15, 2022 (GLOBE...

ROIVW : 2.75 (-3.85%)
ROIV : 11.57 (+0.61%)
FDA Approves Dermavant’s VTAMA® (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults: First Topical Novel Chemical Entity Launched for Psoriasis in the U.S. in 25 Years

- EFFICACY: In the pivotal Phase 3 clinical trial program, VTAMA cream met all primary and secondary endpoints and demonstrated highly statistically...

ROIV : 11.57 (+0.61%)
ROIVW : 2.75 (-3.85%)

Business Summary

Roivant Sciences is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients. Roivant Sciences, formerly known as Montes Archimedes Acquisition Corp., is based in NEW YORK.

See More

Key Turning Points

3rd Resistance Point 3.03
2nd Resistance Point 2.98
1st Resistance Point 2.86
Last Price 2.75
1st Support Level 2.69
2nd Support Level 2.64
3rd Support Level 2.52

See More

52-Week High 4.00
Last Price 2.75
Fibonacci 61.8% 2.56
Fibonacci 50% 2.11
Fibonacci 38.2% 1.66
52-Week Low 0.22

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar